Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

Recruiting

Phase 1

EmicizumabEmicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

Sponsor:

Bleeding and Clotting Disorders Institute Peoria, Illinois

Code:

NCT05500807

Conditions

Von Willebrand Disease, Type 3

Concomitant VWD and Hemophilia

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Emicizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-01. This information was provided to ClinicalTrials.gov by Bleeding and Clotting Disorders Institute Peoria, Illinois on 2025-07-28.